About us / Contact
Behind Mark53 lies a Vienna-based company that was founded at the start of 2013. The company’s strategic direction lies in making a precise, standardised p53 gene test available in the form of the Mark53® analysis, which established the prerequisites for the routine clinical application of the predictive biomarker.
The assumption is that the p53 gene can be employed as a predictive marker, based upon clinical studies conducted at the Medical University of Vienna , headed by Univ. Prof. Dr. Daniela Kandioler. In these studies, the connection between the response to a standard chemotherapy and the p53 gene status were examined in different cancer types.
We look forward to hearing from you and to getting to know you in person!
You can reach us at:
c/o Univ.Prof.Dr. Daniela Kandioler
T +43 (0)664 94 70 290
F +43 (0)1 2533033 5540
UniCredit Bank Austria AG
Austria: Account no. 10001153526, BLZ 12000
International: IBAN AT931200010001153526, BIC BKAUATWW
VAT no. ATU67679915
Vienna Commercial Court, FN 391098w